Effects of Dopaminergic Therapy in Patients with Alzheimer's Disease: A 24 weeks prospective, randomized, double-blind, placebo-controlled, parallel group, international, multi-center phase III study evaluating efficacy and safety of rotigotine 4mg/24 hrs in combination with rivastigmine 9.5 mg/24 hrs in mild to moderate Alzheimer's disease patients.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-504602-11-00

Acronym

DOPAD-3

Enrollment

378

Registered

2023-09-18

Start date

2023-10-25

Completion date

Unknown

Last updated

2025-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild to moderate Alzheimer's disease

Brief summary

● to evaluate efficacy of rotigotine in combination with rivastigmine on frontal lobe cognitive functions as compared to rivastigmine in combination with placebo (change from Baseline to Week 24 in the FAB);

Interventions

DRUGIdentical with the MP patches but without the active substance

DRUGNeupro 2 mg/24 h transdermal patch

DRUGNeupro 4mg/24h transdermal patch

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
● to evaluate efficacy of rotigotine in combination with rivastigmine on frontal lobe cognitive functions as compared to rivastigmine in combination with placebo (change from Baseline to Week 24 in the FAB);	—

Countries

Czechia, Germany, Italy, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026